Biopharmaceutical company Ribomic and biotechnology company Evec have both entered a research agreement.

The two partners will jointly develop an antibody purification technology using aptamer as part of the agreement.

Puridify and GlaxoSmithKline have entered an 18-month collaboration agreement to evaluate the FibroSelect purification technology.

The agreement enables the two partners to develop a package to evaluate the importance of nanofibres in toxicology and clinical manufacture using Puridify’s FibroSelect purification technology.

Ferring Pharmaceuticals and MetaboGen have entered a research agreement to develop a novel treatment for intrahepatic cholestatis of pregnancy (ICP).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the agreement, MetaboGen’s concept for effects of bacteria in the gut on ICP will be used to develop an exploratory study, which will be funded by Ferring Pharmaceuticals.

The agreement enables the two partners to demonstrate the difference in the microbiome patterns in healthy women and in women with ICP.

Blueprint Medicines plans to raise gross proceeds of $125m through the underwritten public offering of common stock shares.

“Puridify and GlaxoSmithKline have entered an 18-month collaboration agreement to evaluate the FibroSelect purification technology.”

Goldman, Sachs & Co, Morgan Stanley, and Cowen and Company are acting as joint book-running managers for the offering.

The company plans to use the funds to advance the clinical trials of BLU-285 in advanced gastrointestinal stromal tumours, to advance clinical trials of BLU-667 in RET-driven cancers and to increase working capital and other general corporate purposes.

Prolacta Biosciences has raised $35m in a mezzanine financing round led by Essex Woodlands and co-led by Aisling Capital and Health Evolution Partners.

The company plans to use the proceeds to expand its presence in Europe, to advance the clinical trials for the development of human milk-based nutritional products and evaluate the role of human milk oligosaccharides (HMOs) to treat different microbiome related diseases.


Image: Puridify and GlaxoSmithKline have entered an 18-month collaboration agreement. Photo: Courtesy of Ian Wilson.